Agios Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $12.9 million, a 43% increase from $9.0 million in the same period last year. For the nine months ending September 30, 2025, the company generated $34.1 million in revenue, up from $25.8 million in the prior year. The growth in revenue is attributed to increased sales volume of its lead product, PYRUKYND® (mitapivat), which is approved for treating hemolytic anemia in adults with pyruvate kinase deficiency.
Despite the revenue growth, Agios reported a net loss of $103.4 million for the third quarter of 2025, compared to a net income of $947.9 million in the same quarter of 2024, which was significantly bolstered by a one-time gain from the sale of its oncology business. For the nine-month period, the net loss was $304.7 million, a stark contrast to the net income of $770.2 million reported in the same period last year. The losses were primarily driven by increased operating expenses, which rose to $129.7 million in the third quarter, up from $111.8 million in the prior year, largely due to higher research and development costs.
Agios has made strategic advancements in its product pipeline, including ongoing clinical trials for PYRUKYND® in treating thalassemia and sickle cell disease. The company is also developing tebapivat, a novel PK activator, and AG-181, a phenylalanine hydroxylase stabilizer for phenylketonuria. In July 2023, Agios entered a license agreement with Alnylam Pharmaceuticals for the development of AG-236, targeting polycythemia vera. The company has also expanded its commercial reach through distribution agreements in the Gulf Cooperation Council region and the European Economic Area.
As of September 30, 2025, Agios reported cash, cash equivalents, and marketable securities totaling $1.3 billion, a decrease from $1.5 billion at the end of 2024. The company anticipates that its current financial resources will be sufficient to support its operations for at least the next twelve months. However, Agios acknowledged the potential need for additional capital to fund ongoing research and development activities, particularly as it prepares for the potential commercialization of PYRUKYND® in new indications.
Looking ahead, Agios expects to continue incurring significant expenses as it advances its clinical development programs and prepares for potential product launches. The company remains focused on expanding its product offerings and enhancing its market presence while navigating the challenges of the biopharmaceutical landscape.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly in classical hematology. Its lead product, PYRUKYND® (mitapivat), targets hemolytic anemias and is FDA-approved for PK deficiency. With a focus on expanding its portfolio, Agios is advancing treatments for thalassemia and sickle cell disease. The company aims to leverage its expertise in cellular metabolism to address significant unmet medical needs in these areas.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.